Robledo-Leal E, Adame-Rodriguez JM, González GM, Aréchiga-Carvajal ET

Language: English
References: 15
Page:
PDF size: 54.35 Kb.

ABSTRACT

Susceptibility assays performed by agar dilution (AD) were compared to M27-A3 broth macrodilution (BMD) methodology (Clinical Laboratory and Standards Institute) and E test (AB BIODISK) in order to determine the feasibility and reliability of agar dilution as an unexpensive test for fluconazole (FLC) susceptibility assays against Candida albicans. A total of 40 strains were used. All of the isolates resulted in agreement for BMD and E test. 19 isolates showed agreement between all three methods. Of the 21 divergent results, 20 resulted in higher MIC for AD and 15 of those were =64 μg/ml. Cell density due to proportional contact of cells with the drug in medium may be responsible for the results obtained and the divergence of AD compared to the other tests. AD can’t reliably substitute neither BMD nor E test, but it may be helpful as a preliminary resistance test for strain susceptibility classification in laboratory research.

REFERENCES

1. de Nadal E., F Calero, J Ramos, and J Arino. 1999. Biochemical and genetic analyses of the role of yeast casein kinase 2 in salt tolerance. J. Bacteriol; 181:6456-6462.

2. Gaxiola R, IF De Larrinoa, JM Villalba and R Serrano. 1992. A novel and conserved salt-induced protein is an important determinant of salt tolerance in yeast. EMBO Journal; 11:3157–3164.

3. Ruiz A, L Yenush and J Arino 2003. Regulation of ENA1 Na+-ATPase Gene Expression by the Ppz1 Protein Phosphatase is Mediated by the Calcineurin Pathway. Eukaryotic Cell; 2: 937-948.

4. National Committee for Clinical Laboratory Standards. 2002. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard, 2nd ed. M27-A2. National Committee for Clinical Laboratory Standards, Wayne, Pa.

5. Gaxiola R et al, Op. cit.

6. Seneviratne CJ, LJ Jin, YH Samaranayake and LP Samaranayake 2008. Cell Density and Cell Aging as Factors Modulating Antifungal Resistance of Candida albicans Bio?lms. Antimicrob Agents Chemother; 52(9):3254-66.

7. Palani P, M Satish, and W LaJean 2007. Role for Cell Density in Antifungal Drug Resistance in Candida albicans Bio?lms. Antimicrob Agents Chemother; 51(7):2454-63.

8. Enjalbert B and M Whiteway 2005. Release from Quorum-Sensing Molecules Triggers Hyphal Formation during Candida albicans Resumption of Growth. Eukaryot Cell; 4(7): 1203–1210.

9. Nickerson, KW, AL Atkin, and JM Hornby. 2006. Quorum sensing in dimorphic fungi: farnesol and beyond. Appl. Environ. Microbiol. 72:3805-3813.

10. Jia XM, ZP Ma, Y Jia, PH Gao, JD Zhang, Y Wang, YG Xu, L Wang, YY Cao, YB Cao, LX Zhang and YY Jiang 2008. RTA2, a novel gene involved in azole resistance in Candida albicans. Biochem Biophys Res Commun; 373(4):631-6.

11. Dunkel N, TT Liu, KS Barker, R Homayouni, J Morschhäuser and PD Rogers 2008. A gain-of-function mutation in the transcription factor Upc2p causes upregulation of ergosterol biosynthesis genes and increased fluconazole resistance in a Eukaryot Cell;7(7):1180-90.

12. Ferrari S, F Ischer, D Calabrese, B Posteraro, M Sanguinetti, G Fadda, B Rohde, C Bauser, O Bader and D Sanglard 2009.Gain of function mutations in CgPDR1 of Candida glabrata not only mediate antifungal resistance but also enhance virulence. PLoS Pathog; 5(1):e1000268.

13. Jia XM, et al, Op.cit.

14. Shukla S, SV Ambudkar and R Prasad 2004. Substitution of threonine-1351 in the multidrug transporter Cdr1p of Candida albicans results in hypersusceptibility to antifungal agents and threonine-1351 is essential for synergic effects of calcineurin inhibitor FK520. J Antimicrob Chemother; 54(1):38-45.

15. Vandeputte P, G Tronchin, G Larcher, E Ernoult, T Bergès, D Chabasse et al 2008. A nonsense mutation in the ERG6 gene leads to reduced susceptibility to polyenes in a clinical isolate of Candida glabrata. Antimicrob Agents Chemother; 52(10):3701-9.